Drug Trial Radar · NCT07401381
A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 8, 2026
Primary completion
May 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Rovi Pharmaceuticals LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.
Conditions
- Hormone Receptor Positive Early Breast Cancer
Interventions
US-sourced oral Femara® + Letrozole SIEDrug
US-sourced Femara® 2.5 mg/day oral for 14 days (treatment period 1) + quarterly injectable Letrozole SIE (treatment period 2)
EU sourced oral Femara® + Letrozole SIEDrug
EU-sourced oral Femara® 2.5 mg/day for 14 days (treatment period 1) + quarterly injectable Letrozole SIE (treatment period 2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve within a dosing interval at Steady-State (SS AUCtau)Time frame: After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® on Day 14 TP1
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Precision NextGen Oncology and Research Center (Investigational Site number USA-001)
Beverly Hills, California · Recruiting
D&H National Research Centers INC (Investigational Site number USA-002)
Margate, Florida · Recruiting
United Medical Research (Investigational Site number USA-005)
Port Orange, Florida · Recruiting
Investigational Site number SRB-004
Belgrade, Serbia · Recruiting
Investigational Site number SRB-002
Belgrade, Serbia · Recruiting
Investigational Site number SRB-001
Kamenitz, Serbia · Recruiting
Investigational Site number SRB-003
Kragujevac, Serbia · Recruiting
Investigational Site number SRB-005
Niš, Serbia · Recruiting
Hospital Universitario Fundación Alcorcón (Investigational Site number ESP-015)
Alcorcón, Spain · Recruiting
NEXT Oncology. Phase I Unit / IOB - Hospital Quironsalud Barcelona (Investigational Site number ESP-002)
Barcelona, Spain · Recruiting
Hospital Universitario Virgen de las Nieves (Investigational Site number ESP-011)
Granada, Spain · Recruiting
Hospital Universitario de Jaén (HUJ) (Investigational Site number ESP-005)
Jaén, Spain · Recruiting
Complejo Asistencial Universitario de León - Hospital de León (Investigational Site number ESP-013)
León, Spain · Recruiting
Hospital Universitario Arnau de Vilanova de Lleida (Investigational Site number ESP-003)
Lleida, Spain · Recruiting
Hospital Quirónsalud Málaga (Investigational Site number ESP-001)
Málaga, Spain · Recruiting
Althaia Xarxa Assistencial Universitària de Manresa F.P (Investigational Site number ESP-012)
Manresa, Spain · Recruiting
Hospital Clínico Universitario Virgen de la Arrixaca (Investigational Site number ESP-009)
Murcia, Spain · Recruiting
NEXT Oncology Phase I Unit - Hospital Universitario Quironsalud Madrid (Investigational Site number ESP-008)
Pozuelo de Alarcón, Spain · Recruiting
Hospital Universitari Sant Joan de Reus (Investigational Site number ESP-004)
Reus, Spain · Recruiting
Consorci Corporació Sanitària Parc Taulí - Hospital de Sabadell (Investigational Site number ESP-006)
Sabadell, Spain · Recruiting
Hospital Clinico Universitario Santiago de Compostela (Investigational Site number ESP-007)
Santiago de Compostela, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.